We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Peel-and-Sniff Cards Could Make Smell Test Single Best Predictor of Being COVID-19 Positive

By LabMedica International staff writers
Posted on 14 Oct 2020
Sensory scientists are encouraging smell checks to fight the COVID-19 spread and are also developing peel-and-sniff cards to supplement other COVID-19 testing and surveillance efforts.

With mounting scientific evidence that anosmia, or loss of smell, is one of the most specific symptoms of COVID-19 infection, sensory scientists at the Pennsylvania State University (University Park, PA, USA) are making efforts to raise awareness about the link between COVID-19 and smell loss. More...
Previous research has found that certain cells at the top of the nasal cavity harbor proteins that the coronavirus targets when invading these cells. The local disruption that occurs is different from the loss of smell that occurs with the common cold, which is due to blockage of the nasal passages. With COVID-19, many patients lose the ability to smell without being stuffy or congested.

The sensory scientists at Penn State believe that greater public awareness of the link between COVID-19 and sudden smell loss could assist in identifying pre-symptomatic or otherwise asymptomatic individuals, which might help contain the virus and ease the burden on sometimes-overwhelmed health care facilities. Additionally, the scientists are members of an international research team, the Global Consortium for Chemosensory Research, that has studied the link between COVID-19 and smell loss. Collaborating with more than 600 clinicians, scientists and patient advocates in 40 countries in an ongoing study, the Penn State researchers so far have surveyed more than 40,000 participants who suffered from recent respiratory illness. The scientists are now developing peel-and-sniff cards that will be distributed to the Penn State community in the near future to supplement other COVID-19 testing and surveillance efforts.

"Our results showed that of all common symptoms of COVID-19, sudden smell loss was the single best predictor of being positive for the disease," said John Hayes, professor of food science and director of the Penn State Sensory Evaluation Center. "Other studies are finding similar results. Together, this suggests that sudden smell loss is a better predictor than fever or cough."

Related Links:
Pennsylvania State University


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.